财信证券：晨会纪要-20250226

Market Overview - The A-share market is experiencing fluctuations, with the major indices showing mixed performance. The Shanghai Composite Index closed at 3346.04, down 0.80%, while the ChiNext Index fell by 1.13% to 2240.59. The STAR Market 50 Index, however, saw a slight increase of 0.26% to 1102.90 [2][6][8] - The total market capitalization of the Shanghai Composite Index is 638,939 million, with a price-to-earnings (PE) ratio of 11.90 and a price-to-book (PB) ratio of 1.26. The ChiNext Index has a PE ratio of 34.05 and a PB ratio of 4.33, indicating a higher valuation compared to the broader market [3] Industry Dynamics - The global ICT market is projected to reach a size of approximately 751.76 billion USD by 2028, with a compound annual growth rate (CAGR) of 6.5% over the next five years. This growth is driven by policy stimulation and emerging technology products [28] - The price of photovoltaic glass is expected to rise in March, with recent reports indicating an increase in pricing due to supply-demand mismatches and production constraints [30] - World Advanced predicts a 8% to 10% increase in wafer shipments for Q1 2025, driven by demand recovery and supply chain adjustments [27] Company Updates - TeBao Bio (688278.SH) reported a net profit of 828 million yuan for 2024, marking a 49% year-on-year increase, attributed to strong sales of its hepatitis B treatment [32] - YanJinPuZi (002847.SZ) plans to establish a wholly-owned subsidiary in Thailand with an investment of approximately 219.95 million yuan, aimed at expanding its overseas business [34] - HuaTe Gas (688268.SH) achieved a net profit of 181.23 million yuan in 2024, a 5.91% increase despite a decline in total revenue [36] - KangTuo Medical (688314.SH) reported a net profit of 88.57 million yuan for 2024, reflecting a 17.30% growth, driven by increased market penetration of its neurosurgical products [38] - JinBo Bio (832982.BJ) announced a significant net profit increase of 144.65% for 2024, reaching 733 million yuan, supported by strong sales growth in medical devices and skincare products [39] - BaiRen Medical (688198.SH) achieved a net profit of approximately 145 million yuan in 2024, a 26.26% increase, with all three business segments showing growth [41] - SaiEnSi (688480.SH) reported a net profit increase of 56.60% for 2024, driven by significant growth in sales and investment returns from joint ventures [43]